Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
An Ocular Drug Delivery is a medical system used to deliver medications directly into the eyes related areas. Current developments in ocular dosage forms, especially colloidal dosage forms, and their applications in overcoming various static and dynamic barriers have been elucidated.
The increase in geriatric population leads to the rise in particularly for the treatment of chronic eye diseases by patients who are suffering dryness, conjuctiva, eye flu etc, the expanding application of Ocular Drug Delivery and the ability to customize medication doses are the major factor fueling the growth for the market, according to research, the global Ocular Drug Delivery market expected to hit 14.2 billion by 2022, register a CAGR of 14.7% over 2018-2022.
In terms of geography, the North America is holding the position of world largest market. This is mainly attributed to the favorable response from insurance companies; the healthcare insurance programs such as Medicare are driving the market. Several indications for treatment using topical segment are covered under this program. According to research, the North America is expected to reach USD$ 7.08 billion by 2022.
The Asia Pacific region exhibits the fastest growing market, at a CAGR of 19.5% during the forecast period, supplemented by factors such as development in health care insurance, increasing geriatric population, and rising disposable income in the region.
Base on the future development, technological advancements that may show significant increases in efficacy, safety and approval of potential indications. The miniaturization of the device pump and the improved battery consumption are where the majority of technological advancements will take place.
Global top manufacturers operating in Ocular Drug Delivery market are Aciont, Envisia Therapeutics, EyeGate Pharma, Graybug Vision, iVeena, Kala Pharmaceuticals, KMG Pharma, Leo Lens Technology, Mati Therapeutics, Ocular Therapeutix, Oculis Pharma, pSivida, Spindrift Therapeutics, ViSci, Ltd among others.
Request Sample 
Request Discount 
Inquire Before Buy
